Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript

SA Transcripts158.96K FollowersFollow5ShareSaveCommentsQ4: 2026-03-12 Earnings SummaryInsightsTranscript InsightsPlay CallPlay CallEPS of -$0.17 beats by $0.05 | Revenue of $0.00 misses by $2,000.00 Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call March 12, 2026 5:00 PM EDT Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy OfficerDavid Chang - Co-Founder, President, CEO & DirectorZachary Roberts - Executive VP of Research & Development and Chief Medical OfficerGeoffrey Parker - Executive VP & CFO Conference Call Participants Tyler Van Buren - TD Cowen, Research DivisionBiren Amin - Piper Sandler & Co., Research DivisionMichael YeeSalveen Richter - Goldman Sachs Group, Inc., Research DivisionMatt PhippsMatthew Biegler - Oppenheimer & Co. Inc., Research DivisionAsthika Goonewardene - Truist Securities, Inc., Research DivisionJohn Newman - Canaccord Genuity Corp., Research DivisionLut Ming Cheng - JPMorgan Chase & Co, Research Division Presentation Operator Hello, and thank you for standing by. Welcome to Allogene Therapeutics Fourth Quarter 2025 Conference Call. [Operator Instructions] Please be aware that today's conference call is being recorded. I would now like to turn the call over to Christine Cassiano, Chief Corporate Affairs and Brand Strategy Officer. Ms. Cassiano, please go ahead. Christine CassianoExecutive VP, Chief Corporate Affairs & Brand Strategy Officer Thank you, operator, and welcome, everyone, to Allogene's conference call. After the market closed, Allogene issued a press release that provided a business update and financial results for the fourth quarter and year-end 2025. This press release and today's webcast are available on our website. Following our prepared remarks, we will host a Q&A session, and we will aim to keep the call to under an hour. I'm joined today by Dr. David Chang, President and Chief Executive Officer; Dr. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer; and Jeff Parker, Chief Financial Officer. During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and